NASDAQ$PETS

PetMed Express · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Net sales and net income decreased compared to the same quarter last year.

PetMed Express reported a decrease in net sales and net income for the quarter ended December 31, 2021. Net sales decreased by 7.9% to $60.7 million, and net income decreased by 44% to $4.3 million, or $0.21 diluted per share. The company is executing a business transformation across people, process, and product to develop into a broader expert health and wellness offering.

  • Net sales decreased by 7.9% to $60.7 million compared to $65.9 million for the quarter ended December 31, 2020.
  • Net income decreased by 44% to $4.3 million, or $0.21 diluted per share, compared to $7.6 million, or $0.38 diluted per share, for the quarter ended December 31, 2020.
  • Adjusted EBITDA decreased by 31% to $7.6 million, or $0.37 diluted per share, compared to $11.0 million, or $0.55 diluted per share, for the quarter ended December 31, 2020.
  • The Board of Directors declared a quarterly dividend of $0.30 per share on the Company’s common stock.

Headline financials

Total Revenue

$60.7M

Previous: $65.9M-7.9%
EPS (adj)

$0.21

Previous: $0.38-44.7%
Capital Expenditures

-$1.27M

Previous: -$1.85M+31.5%
Free Cash Flow

$8.52M

Previous: $19.8M-56.9%
Net Income

$4.26M

Previous: $7.61M-44.1%
Operating Income

$5.15M

Previous: $9.29M-44.6%
Gross Profit

$17.7M

Previous: $19.6M-9.7%
Cash & Equivalents

$109M

Previous: $107M+2.3%
Total Assets

$168M

Previous: $167M+0.6%
Stock-Based Comp

$1.44M

Previous: $781K+84.4%

Revenue & EPS history

PetMed Express · Revenue · Quarterly

$60.7M

Q3 2022-7.9%vs Q3 2021
Beat estimate in 6 of 16 quarters(38%)
ActualEstimate

Forward guidance

The company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

-0.0%

Avg return

Earnings day

-1.6%

Avg return

5 days after

-0.4%

Avg return

30 days after

42%

27 / 65 earnings

Positive

+40.8%

Q2 2020

Best reaction

-26.4%

Q2 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-16.4%-21.1%
Q3 2026-3.6%-8.7%-15.5%
Q4 2025+0.0%-4.9%-6.6%
Q2 2026-1.4%-2.7%-8.2%
Q1 2026-1.1%-1.4%-6.9%
Q3 2025-14.8%-20.1%-22.7%
Q2 2025+34.5%+27.2%+35.0%
Q1 2025-11.0%-13.0%-4.5%
Q4 2024-0.7%-1.7%-7.4%
Q3 2024+0.2%-1.2%+8.9%
Q2 2024-26.4%-23.0%-22.6%
Q1 2024-2.8%-6.4%-20.0%
Q4 2023+6.7%+1.0%-6.6%
Q3 2023-11.1%-13.3%-19.6%
Q2 2023-10.5%-4.7%-15.5%
Q1 2023+4.3%+4.2%+0.9%
Q4 2022+6.9%+2.0%+3.0%
Q3 2022+7.2%+7.7%+3.4%
Q2 2022+5.1%+5.1%+5.2%
Q1 2022+7.1%+13.0%+3.2%
Q4 2021+2.8%+0.5%+56.5%
Q3 2021-14.3%-11.1%+3.2%
Q2 2021-2.2%-3.5%-1.9%
Q1 2021-16.0%-23.8%-17.4%
Q4 2020+3.6%-4.0%-7.5%
Q3 2020-11.0%-11.2%+4.0%
Q2 2020+40.8%+32.8%+21.7%
Q1 2020+2.5%-1.5%+5.1%
Q4 2019-9.0%-9.7%-18.9%
Q3 2019-6.2%-3.4%-3.1%
Q2 2019+2.6%+1.1%-9.7%
Q1 2019-13.0%-11.8%-6.4%
Q4 2018-0.9%+1.4%+15.1%
Q3 2018-4.8%-10.2%-12.0%
Q2 2018+4.4%-5.0%+9.0%
Q1 2018+18.6%+19.3%-10.7%
Q4 2017+34.7%+41.2%+48.4%
Q3 2017-5.1%-5.4%-3.6%
Q2 2017-3.2%-4.0%+6.6%
Q1 2017+6.0%+5.8%+3.3%
Q4 2016+2.9%
Q3 2016-4.8%
Q2 2016+2.1%
Q1 2016+0.5%
Q4 2015+2.6%
Q3 2015+14.3%
Q2 2015-3.7%
Q1 2015+5.0%
Q4 2014+1.6%
Q3 2014-12.0%
Q2 2014-10.3%
Q1 2014+12.7%
Q4 2013-0.5%
Q3 2013+7.0%
Q2 2013+6.9%
Q1 2013-16.3%
Q4 2012-5.4%
Q4 2010-5.4%
Q3 2011-0.2%
Q3 2012-0.2%
Q2 2012-0.8%
Q2 2011-0.8%
Q1 2012-0.1%
Q1 2011-0.1%
Q4 2011-0.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro